HF Advisory Group LLC Has $1.01 Million Stake in Sanofi (NASDAQ:SNY)

HF Advisory Group LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 62.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,369 shares of the company’s stock after purchasing an additional 7,803 shares during the period. HF Advisory Group LLC’s holdings in Sanofi were worth $1,013,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SNY. SRS Capital Advisors Inc. boosted its position in Sanofi by 289.1% in the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new position in Sanofi in the 3rd quarter valued at $26,000. Fairfield Bush & CO. bought a new position in Sanofi in the 1st quarter valued at $26,000. Rise Advisors LLC boosted its position in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the last quarter. Finally, Salem Investment Counselors Inc. bought a new position in Sanofi in the 4th quarter valued at $27,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of recent research reports. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley began coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $55.00.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded down $0.48 during trading on Thursday, reaching $45.63. 744,330 shares of the stock were exchanged, compared to its average volume of 1,843,888. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The firm has a market cap of $115.43 billion, a PE ratio of 19.54, a PEG ratio of 1.71 and a beta of 0.61. The stock has a 50-day moving average price of $47.55 and a 200-day moving average price of $48.69. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. Research analysts expect that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.